The proposed life sciences research and development centre in North of England region of UK will support acceleration of the company’s research in the areas of biotechnology, health and life sciences
The Phase 3 trial will be conducted under the auspices of the first Regenerative Medicine Advanced Therapy (RMAT) designation approved by the USFDA for an EV therapeutic
Terran to advance the development of two of Sanofi's Phase 3 CNS therapeutics
The business is a recognized leader in managing Covid-19 and mRNA research programs
With the commercialization of Qvella technology for Positive Blood Culture (PBC) processing, healthcare facilities can now get results up to 24 hours faster than current methods
Pre-exposure prevention trial reduced risk of symptomatic Covid-19, with no severe disease or Covid-19-related deaths in the Evusheld group
Immune response confirmed in stand-alone influenza vaccine and combination vaccine with a potential path forward for both
New kit enhances menu of FFPE solutions and allows oncology researchers to extract higher yields of concentrated DNA compared to traditional techniques
To meet the growing global demand for respiratory active pharmaceutical ingredients (APIs), Inke is to invest €9 million into its production plant to reinforce focus on inhalation micronised APIs
The life sciences and pharmaceutical sectors suffer from hard-to-source biological materials, which translates into high costs in research and development
The purpose of the study is to investigate safety and tolerability of SNIPR001 in healthy volunteers and to evaluate the effect of SNIPR001 on reducing E. coli colonization in the gut
The MicroGEM Saliva test is the first point of care PCR saliva test for Covid-19 delivering results in minutes
By strengthening the company's fibrotic disease development pipeline, Bridge will enhance its strategic focus on the development of comprehensive treatment solutions for idiopathic pulmonary fibrosis (IPF)
Bionova Scientific’s process development capabilities are particularly highly regarded in the industry, and it has a rich track record regarding complex next-generation antibody drugs, which are typically challenging to manufacture
Under the terms of the partnership agreement, Comera will develop a differentiated formulation of an Intas product using Comera's innovative proprietary SQore formulation platform
This marks an expansion of the companies' existing collaboration and further validates the use of Albumedix Recombumin rHA products in the manufacturing process and final formulation of critical vaccines
Momelotinib complements GSK’s existing expertise in haematology, with Sierra Oncology anticipating US regulatory submission in Q2 this year and EU submission in the second half of 2022
Through the contract, the company will supply two key GMP intermediates for one of the 'patented drugs' of the innovator pharmaceutical customer
The DalPhos ligands were developed by Prof. Mark Stradiotto and his research team at the Department of Chemistry, Dalhousie University
An RMAT confers eligibility for accelerated approval and priority review of biologics licensing applications (BLA)
Subscribe To Our Newsletter & Stay Updated
